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Abstract
Background: The view that 2 l of crystalloid and 1.5 l of colloid can be infused while awaiting compatible blood
for patients with major postpartum haemorrhage is based on expert opinion documents. We describe real-world
changes in levels of coagulation parameters after the administration of different volumes of clear fluids to women
suffering from major postpartum haemorrhage.
Methods: We performed a nationwide retrospective cohort study in the Netherlands among 1038 women
experiencing severe postpartum haemorrhage who had received at least four units of red cells or fresh frozen
plasma or platelets in addition to red cells. The volume of clear fluids administered before the time of blood
sampling was classified into three fluid administration strategies, based on the RCOG guideline: < 2 L, 2–3.5 L
and > 3.5 L. Outcomes included haemoglobin, haematocrit, platelet count, fibrinogen, aPTT and PT levels.
Results: Haemoglobin, haematocrit, platelet count, fibrinogen and aPTT were associated with volumes of clear
fluids, which was most pronounced early during the course of postpartum haemorrhage. During the earliest
phases of postpartum haemorrhage median haemoglobin level was 10.1 g/dl (IQR 8.5–11.6) among the women who
received < 2 L clear fluids and 8.1 g/dl (IQR 7.1–8.4) among women who received > 3.5 L of clear fluids; similarly
median platelet counts were 181 × 109/litre (IQR 131–239) and 89 × 109/litre (IQR 84–135), aPTT 29 s (IQR 27–33) and
38 s (IQR 35–55) and fibrinogen 3.9 g/L (IQR 2.5–5.2) and 1.6 g/L (IQR 1.3–2.1).
Conclusions: In this large cohort of women with severe postpartum haemorrhage, administration of larger volumes of
clear fluids was associated with more severe deterioration of coagulation parameters corresponding to dilution. Our
findings provide thus far the best available evidence to support expert opinion-based guidelines recommending
restrictive fluid resuscitation in women experiencing postpartum haemorrhage.
Trial registration: Netherlands Trial Register (NTR4079), registration date July 17, 2013.
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Background
Postpartum haemorrhage continues to be a leading cause
of maternal health problems worldwide [1]. Depending on
the primary cause of haemorrhage, acquired coagulopathy
may develop during the course of postpartum haemor-
rhage and aggravate bleeding [2]. Rapid intravenous infu-
sion of clear (crystalloid and colloid) fluids is generally
applied during on-going haemorrhage to establish haemo-
dynamic stability, restore adequate intravascular volume
and improve oxygen carrying capacity and oxygen tissue
delivery [3]. When given in large volumes, clear fluids ini-
tiate dilution of clotting factors resulting in impairment of
coagulation and coagulopathy [4–6]. On top of that, rapid
consumption of fibrinogen, clotting factors and platelets
as a result of persistent blood loss, aggravates coagulopa-
thy [5]. The use of colloid fluids has proven to negatively
influence coagulation capacity and endothelial function [7,
8]. These findings have led to less aggressive fluid manage-
ment in patients with traumatic haemorrhagic shock [9].
International guidelines on management of women with
severe postpartum haemorrhage elucidate the lack of
quantitative evidence on the effect of different fluid man-
agement strategies on parameters of coagulopathy. For in-
stance, the RCOG green-top guideline advises to follow
the expert opinion-based recommendation to administer
up to 3.5 l of warmed clear fluids, starting with 2 l of
warmed isotonic crystalloids until blood products are
available in case of persistent postpartum blood loss ex-
ceeding 1000 ml [10]. The experts formed their opinions
based on experiments in laboratories, animals, healthy
volunteers, and observations from trauma patients. How-
ever, findings from these studies may not apply to preg-
nant women, since pregnancy induces haemodynamic and
haematologic changes that protect them against haemor-
rhage during birth. Maternal blood volume increases
between 1.2 and 1.6 l above non-pregnant values, creating
a hypervolemic state during pregnancy [4]. To enable
evidence-based recommendations on fluid management
strategies in women with major postpartum haemorrhage,
more insight is needed on the changes of coagulation pa-
rameters after administration of different volumes of fluids
[4]. To the best of our knowledge no previous studies have
been conducted into different fluid management strategies
and their possible effect on coagulation parameters in
women experiencing postpartum haemorrhage.
The aim of this study was to describe the association
between administration of different volumes of clear
fluids and levels of coagulation parameters in women ex-
periencing postpartum haemorrhage.
Methods
Design and study population
We studied volumes of clear fluids and results of co-
agulation parameter measurements during postpartum
haemorrhage in a cohort of women who had been in-
cluded in a nationwide retrospective cohort study in
61 hospitals in the Netherlands, the TeMpOH-1 (Transfu-
sion strategies in women during Major Obstetric Haemor-
rhage) study. Included in the TeMpOH-1 study were
women who received at least four units of red cells or any
transfusion of fresh frozen plasma (FFP) and/or platelets
in addition to red cells because of obstetric haemorrhage
defined as ≥1000 mL blood loss during pregnancy, child-
birth or puerperium between January 1st, 2011 and Janu-
ary 1st, 2013. For the present analyses, we selected women
from the TeMpOH-1 cohort who met criteria for primary
postpartum haemorrhage: any amount of blood loss ex-
ceeding 1000 mL within the first 24 h after childbirth.
Women with no coagulation parameters measured during
active postpartum haemorrhage and women with missing
data on volumes and timing of clear fluids were excluded.
In case transfusion of blood products occurred before on-
set of clear fluid administration, patients were also ex-
cluded. The Ethical Committee of Leiden University
Medical Centre (P12.273) and the institutional review
boards of all participating hospitals approved of the study.
The study was registered in the Netherlands Trial Register
(NTR4079). Details regarding study design have been re-
ported elsewhere [11]. The need to obtain informed con-
sent was waived by the ethics committee because of the
retrospective design. Women 18 years of age and older
who met the inclusion criteria were selected.
Data collection
To identify all consecutive women who had been trans-
fused with the aforementioned amount of blood prod-
ucts because of postpartum haemorrhage in the
participating hospitals, data from the hospitals’ blood
transfusion services were merged with data from birth
registers of contributing hospitals. Qualified medical stu-
dents and research nurses collected routine data from
the medical records with regard to (obstetric) history
and course of the current pregnancy, as well as data per-
taining to characteristics of participating women, mode
of birth, primary cause of haemorrhage, placentation,
characteristics of shock (defined as systolic blood pres-
sure < 90 mmHg or heartrate > 120 bpm), surgical and
haemostatic interventions to stop bleeding and coagula-
tion parameters. Results of all measurements of haemo-
globin level (Hb, g/dl), haematocrit (Ht, fraction),
platelet count (× 109/litre), activated partial thrombo-
plastin time (aPTT, seconds), prothrombin time (PT,
seconds) and fibrinogen (g/L) levels from the first meas-
urement of blood loss onwards were documented; this
included parameters drawn from cases before they had
bled a total volume of 1000 mL. Outliers of levels of co-
agulation parameters were verified in the medical re-
cords. In addition, detailed information on crystalloid
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and colloid fluids administered during the course of
postpartum haemorrhage was collected: total volume
and type of clear fluids given, as well as timing informa-
tion with regard to onset and end of infusion. Informa-
tion on timing and volume of repetitive blood loss
measurements was also retrieved from the medical files.
In most cases blood loss was measured by weighing
soaked gauzes during and after birth and by use of a col-
lector bag and suction system in the operating theatre.
Severe acute maternal morbidity and maternal mortality
The composite endpoint severe acute maternal morbid-
ity and mortality comprised emergency peripartum hys-
terectomy, ligation of the uterine arteries, B-Lynch
suture (in the Netherlands only used as emergency pro-
cedure), arterial embolization or admission into an in-
tensive care unit.
Statistical analyses
The aim was to describe values of measured laboratory
parameters according to increasing “volume of blood
loss” and “volume of clear fluids administered” during
the course of severe postpartum haemorrhage. In order
to have an estimate of the “volume of blood loss” and of
“volume of clear fluids administered” for all blood sam-
ples (and their respective laboratory results) we used lin-
ear interpolation of the actual measurement of “volume
of blood loss” and “volume of clear fluids administered”
before and after each blood sample. The volume of
blood loss at the time of blood sampling was categorised
in 8 groups: 0–1.0 L, 1.0–1.5 L, 1.5–2.0 L, 2.0–2.5 L,
2.5–3.0 L, 3.0–3.5 L, 3.5–4.0 L and > 4.0 L. Coagulation
parameters were allocated to the category representing
the volume of blood loss at sampling. In case of multiple
laboratory measurements per patient within one blood
loss category, the mean of the values was used in the
analyses, calculating a patient just once per category.
Subsequently, within these blood loss categories, the vol-
ume of clear fluids administered at the time of blood
sampling was calculated and classified into three fluid
administration strategies: < 2.0 L, 2.0–3.5 L and > 3.5 L.
These three administration strategies were based on the
RCOG green-top guideline, which recommends to ad-
minister up to 3.5 l of warmed clear fluids, starting with
2 l of warmed isotonic crystalloids if blood is not avail-
able [10] . Since blood sampling during postpartum
haemorrhage was not performed at predefined time
points and samples were obtained on request of the
physician on call during postpartum haemorrhage, pa-
tients could have different frequencies and panels of co-
agulation parameters. Reference ranges of aPTT varied
somewhat for the 61 participating hospitals as a result of
use of different types of reagents. Therefore, an aPTT
ratio was calculated by dividing the aPTT level of cases
by the mean of the hospital specific reference range.
Results
Patient characteristics
A total of 1038 women with severe postpartum haemor-
rhage had at least one valid measurement of coagulation
parameters sampled during active bleeding in addition
to data on volume and timing of clear fluids adminis-
tered (Fig. 1). Baseline characteristics are reported in
Table 1. Women were on average 31 years of age, gave
birth at a median gestational age of 39.7 weeks and 25%
delivered by caesarean section. Uterine atony was the
primary cause of bleeding in 66% of the cases and 34%
of women developed a composite endpoint of severe
acute maternal morbidity or mortality. The median total
volume of blood loss among all 1038 women with post-
partum haemorrhage was 3.0 L (interquartile range 2.5–
4.0). In our cohort, women in the lowest fluid categories
showed fewer signs of shock and were administered
fewer blood products when compared to women in the
other fluid categories for all coagulation parameters
(data presented in table adjacent to Fig. 3).
Fig. 1 Inclusion flowchart for ‘fluid management and dilutional
coagulopathy in severe postpartum haemorrhage: a nationwide
retrospective cohort study’
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Volume expansion and volume of blood loss
Figure 2 presents volumes of blood loss and volumes of
infused fluids. Among women who had one or more la-
boratory parameters measured during the first phases of
postpartum haemorrhage (n = 245 for 0 to 1 L; n = 306
for 1 to 1.5 L; and n = 351 for 1.5 to 2 L) the mean vol-
ume of replacement therapy (clear fluids and blood
products) administered was less or equal the total vol-
ume of blood loss. During the next phases of postpar-
tum haemorrhage (blood loss between 2 and 2.5 L) the
mean volume of replacement therapy (clear fluids and
blood products) was higher than the volume of blood
loss. This “overload” enlarged with increasing blood loss
volumes, reaching 32% more volume replacement com-
pared to blood loss in the phase in which the women
had lost 3.5-4 L (5.3 L infused /4 L lost). For all categor-
ies of blood loss, mean volume of clear fluids adminis-
tered did not exceed and in most cases was similar to
the maximum blood loss. With increasing blood loss,
the proportion of blood products (versus clear fluids)
administered showed a gradual increase, from 118/
1178 mL (10%) at 1000-1500 mL blood loss to 1605/
5279 mL (30%) after blood loss up to 4000 mL.
Laboratory parameters after different volumes of clear
fluids in the course of postpartum haemorrhage
Figure 3 presents results of laboratory tests according to
received volumes of clear fluids (0 to 2 L, 2 to 3.5 L or
more than 3.5 L) during the first two litres of postpar-
tum haemorrhage. From 1031 women a total of 2714
haemoglobin measurements were available. Administra-
tion of higher volumes of clear fluids was associated
with lower haemoglobin and haematocrit levels and this
was most pronounced in the earlier phases of postpar-
tum haemorrhage (Fig. 3 and Additional file 1: Table S1
and Additional file 2: Figure S2). For example, when the
women had lost less than 1.0 L of blood, the median
haemoglobin level was 10.1 g/dl (IQR 8.5–11.6) if they
had received < 2.0 L of clear fluids, whereas after receiv-
ing 2.0–3.5 L clear fluids median haemoglobin was
8.4 g/dl (IQR 6.4–9.7).
Platelet counts of 804 women decreased over the three
increasing fluid administration categories. In samples
drawn in the earliest phase of postpartum haemorrhage
(0-1 L blood loss), median platelet counts were 181 (IQR
131–239), 154 (IQR 99–205) and 89 × 109/litre (IQR 84–
135) in the three categories of increasing volumes of
fluids administered. A similar pattern was observed in
consecutive blood loss categories.
Fibrinogen measurements of 438 women were avail-
able for analyses. Administering higher volumes of clear
fluids was associated with a decreasing level of fibrino-
gen in measurements in the early phases of postpartum
haemorrhage (up to 2 L of blood loss). The largest
Table 1 Clinical characteristics of the cohort of 1038 women
with ongoing postpartum haemorrhage included in this analysis
Patients n = 1038
Maternal characteristics
Age (years) 31.0 (28.0–35.0)a
BMI (kg/m2) 23.2 (21.0–26.3)
Ethnicity Caucasian 747 (72%)b
Nulliparity 534 (51%)
Gestational age 39.7 (38.1–40.7)
Mode of birth
Caesarean section 254 (24%)
Vaginal 780 (75%)
Comorbidity
Pre-eclampsia/ HELLP 104 (10%)
Anti-coagulant use 6 (0.6%)
Transfer to hospital
No transfer (birth in hospital) 753 (73%)
Transfer to hospital during labour 157 (15%)
Postpartum transfer (birth at home) 128 (12%)
Primary cause of bleeding
Uterine atony 684 (66%)
Retained placenta 168 (16%)
Pathological ingrowth of placenta 89 (9%)
Surgical bleeding and abruption/
coagulopathy
97(9%)
Placentation
Abnormal localisation placenta 65 (6%)
Pathological ingrowth placenta 97 (9%)
Composite endpoint severe maternal
morbidity and mortality
355 (34%)
Embolisation 124 (12%)
Hysterectomy 57 (5%)
Emergency B-Lynch 27 (3%)
Ligation arteries 7 (0.7%)
ICU admission 295 (28%)
Maternal mortality 6 (0.6%)
Haemostatic interventions
Fibrinogen administered 98 (9%)
Tranexamic acid administered 473 (46%)
Recombinant FVIIa administered 29 (3%)
Bleeding characteristics
Bleeding rate (ml/min) c 2.4 (1.3–4.8)
Shock 927 (89%)
Total volume blood loss (L) 3.0 (2.5–4.0)
Total volume of clear fluids (L) 3.0 (2.0–4.0)
Total units of blood products (n) 6.0 (4.0–8.0)
aValues are presented as median with (interquartile range), bpercentage,
c maximum
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change was displayed for measurements performed in
the earliest phase of postpartum haemorrhage (blood
loss 0-1000 mL): 3.9 g/L (IQR 2.5–5.2), 2.6 g/L (IQR
1.6–3.7), 1.6 g/L (IQR 1.3–2.1) over the three fluid man-
agement categories.
PT and aPTT were longer after administration of lar-
ger volumes of clear fluids. For both, the largest differ-
ence was observed between measurements in the most
restrictive fluids category (< 2 L) and the most liberal
category (> 3.5 L). In samples drawn between 0 and 1 L
blood loss, PT was 13 (IQR 11–15) and 17 s (IQR 12–
19) and aPTT 29 (IQR 27–33) and 38 s (IQR 35–55) in
lowest and highest fluid administration categories re-
spectively. Levels of PT and aPTT of women adminis-
tered 2–3.5 L of fluids were similar to blood samples of
women who were administered less than 2 L of fluids.
Results of the aPTT ratio showed similar results
(Additional file 3: Figure S3).
Discussion
This nationwide retrospective multicentre cohort study
describes coagulation parameters after administering
different volumes of resuscitation fluids in 1038 women
with ongoing severe postpartum haemorrhage. The
administration of larger volumes of clear fluids was asso-
ciated with deterioration of levels of haemoglobin,
haematocrit, platelet count, fibrinogen, aPTT and PT
which was most pronounced during the earlier phases of
postpartum haemorrhage.
Strengths and limitations of our study
A strength of the study is that we included a large cohort
of women who had suffered severe postpartum haemor-
rhage and who had been treated with different volume
replacement strategies. Women in our study were cate-
gorised based on similar volumes of blood loss at time of
blood sampling, thereby making them comparable on a
clinical level during the course of haemorrhage. Volume
replacement had been carefully documented in the med-
ical files in all the participating hospitals ensuring correct
classification of women according to the different replace-
ment strategies. Both these strengths allow for reliable de-
scription of abnormalities in coagulation in relation to
volume replacement therapy.
We stratified our findings according to volume of blood
loss. Volume of blood loss was measured in most cases by
Fig. 2 Volume of clear fluids and blood products administered per blood loss category. For example: in the blood loss category 0.0 to 1.0 L 245
women had one or more laboratory parameter tested, and at the time of blood sampling for the laboratory parameters these women had received
674 ml clear fluids, 50 ml blood products, yielding a total volume administered of 723 mL
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weighing soaked gauzes during and after birth and by use
of a collector bag and suction system in the operating the-
atre, in addition to visual estimation. Thus, there may be
misclassification of volume of blood loss in both direc-
tions, over- and underestimation and it is therefore diffi-
cult to know whether and how our findings are affected
by this misclassification. Our findings are also affected by
the fact that inherently more blood samples are drawn
from women with more severe bleeding. This may have
led to overestimation of the number of women with ab-
normal laboratory test results. Because of the design of
the study we did not have influence on the number and
specific panels of coagulation samples requested. There-
fore, our results show different selections of women in all
blood loss categories that we present. Although it is
tempting to infer that high volumes of clear fluids are
causally related to the observed dilution our study does
not allow such inference. There are many other factors
that may have influenced coagulation parameters such as
the primary cause of haemorrhage, bleeding and treat-
ment characteristics and the presence of comorbidities.
This descriptive study does not allow for disentanglement
of the separate effects of these joint risk factors. We ex-
cluded 353 women because they had no valid lab meas-
urement available during active bleeding or data were
missing on volume or timing of clear fluids administered.
To be certain their exclusion did not induce a systemic
error to our data resulting from selection bias, we com-
pared these women on the most relevant Table 1 items:
mode of birth, nulliparity, primary cause of haemorrhage,
the composite endpoint of severe maternal morbidity and
mortality, bleeding rate at sampling, presence of shock
and total volume of blood loss. No differences were ob-
served compared to the women that were included in the
study, ruling out the presence of a systemic error influen-
cing the results.
Fig. 3 Coagulation parameters according to clear fluid administration (0-2 L, 2 L–3.5 L, > 3.5 L) and increasing volume of blood loss (0–1.0, 1.0–1.5,
1.5–2.0 L). Laboratory parameters are presented in box plots. Circles are outliers. The box represents the 25th and 75th percentiles and the whiskers are
the upper and lower adjacent values. *Statistics: (1) Patient count; (2) Percentage of women who received blood products; (3) Percentage of women
who experienced shock surrounding blood sampling; (4) mean bleeding rate in ml/min surrounding blood sampling
Gillissen et al. BMC Pregnancy and Childbirth  (2018) 18:398 Page 6 of 9
Comparison with other studies
To the best of our knowledge no previous studies have de-
scribed the association between different fluid management
strategies and coagulation parameters during the various
phases of severe postpartum haemorrhage. Yet, our find-
ings corroborate results of previous studies into the effect
of dilution on coagulation parameters. An in vitro study
evaluating the effect of haemodilution on coagulation fac-
tors found that PT and aPTT were significantly prolonged
after 60% and 80% dilution [12]. Another in vitro study in-
vestigated the effect of haemodilution on the course of glo-
bal coagulation tests and clotting factors. Levels of
dilution-dependent coagulation factors and aPTT were
found to decrease in an almost linear manner. Critically
low activities for coagulation factors and a critically low
level of fibrinogen were measured at dilutions of between
60 and 75% [13]. An in vivo study reported coagulation pa-
rameters in hypotensive patients with penetrating torso in-
juries who were treated with immediate versus delayed
fluid resuscitation. Patients in the immediate fluid adminis-
tration group showed worse levels of haemoglobin, platelet
count, PT and APTT compared to patients in the delayed
fluid administration group [14]. No previous studies were
found that examined the change in coagulation parameters
as a result of different fluid management strategies in
women experiencing postpartum haemorrhage.
Clinical implications
In our cohort of women experiencing postpartum haem-
orrhage, we displayed changes occurring on coagulation
parameter level after administering different volumes of
fluids. Administration of larger volumes of clear fluids
was associated with more severe worsening of levels
of haemoglobin, haematocrit, platelet count, fibrino-
gen, aPTT and PT which was most pronounced
during the earlier phases of postpartum haemorrhage.
Our findings provide quantitative evidence to
reinforce expert opinion-based guidelines recommend-
ing restrictive fluid resuscitation strategies in case of
postpartum haemorrhage;
Conclusions
In this nationwide retrospective cohort study in 1038
women on the change in coagulation parameters with
increasing volumes administered during the course of
postpartum haemorrhage necessitating blood transfu-
sion, the administration of large volumes of clear fluids
was associated with changes in coagulation parameters
corresponding to dilutional coagulopathy. Our findings
provide thus far the best available evidence to support
expert opinion-based guidelines recommending restrict-
ive fluid resuscitation in women experiencing postpar-
tum haemorrhage.
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